阿里纳制药

ARNA NASDAQ
61.82
-0.13
-0.21%
盘后: 61.82 0 0.00% 17:04 07/19 EDT
开盘
61.91
昨收
61.95
最高
62.75
最低
61.60
成交量
31.00万
成交均量(3M)
53.32万
52周最高
62.75
52周最低
31.97
换手率
0.63%
市值
30.64亿
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供阿里纳制药 ARNA股票价格,阿里纳制药股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Arena Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing small molecule drugs across a range of therapeutic areas. The Company has three primary investigational clinical programs: etrasimod (APD334) in Phase II evaluation for ulcerative colitis, APD371 entering Phase II evaluation for the treatment of pain associated with Crohn's disease, and ralinepag (APD811) in Phase II evaluation for pulmonary arterial hypertension (PAH). The Company's drug, Lorcaserin, is approved for marketing in the United States and South Korea for the indication of weight management. The Company's drug candidates in clinical development include APD334 for autoimmune diseases, ralinepag for vascular diseases and APD371 for pain. The Company's programs under collaboration include nelotanserin for dementia-associated psychosis, temanogrel for thrombotic diseases, and an undisclosed orphan GPCR for central nervous system (CNS) indication(s).
展开 >

最近浏览

名称
价格
涨跌幅